Maria Alessandra Calegari

845 total citations
43 papers, 361 citations indexed

About

Maria Alessandra Calegari is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Maria Alessandra Calegari has authored 43 papers receiving a total of 361 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Maria Alessandra Calegari's work include Colorectal Cancer Treatments and Studies (28 papers), Gastric Cancer Management and Outcomes (12 papers) and Hepatocellular Carcinoma Treatment and Prognosis (8 papers). Maria Alessandra Calegari is often cited by papers focused on Colorectal Cancer Treatments and Studies (28 papers), Gastric Cancer Management and Outcomes (12 papers) and Hepatocellular Carcinoma Treatment and Prognosis (8 papers). Maria Alessandra Calegari collaborates with scholars based in Italy, United States and Malaysia. Maria Alessandra Calegari's co-authors include Alessandra Cassano, Armando Orlandi, Giampaolo Tortora, Emilio Bria, Maurizio Martini, Luigi Maria Larocca, Lisa Salvatore, Carlo Barone, Antonia Strippoli and Ina Valeria Zurlo and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and British Journal of Cancer.

In The Last Decade

Maria Alessandra Calegari

39 papers receiving 355 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maria Alessandra Calegari Italy 10 220 109 89 70 65 43 361
Kristen K. Ciombor United States 10 191 0.9× 78 0.7× 84 0.9× 62 0.9× 25 0.4× 26 315
Feiyu Niu China 12 266 1.2× 314 2.9× 175 2.0× 130 1.9× 39 0.6× 25 513
Kokoro Kobayashi Japan 11 205 0.9× 106 1.0× 45 0.5× 138 2.0× 42 0.6× 39 341
Israel Cañadas Spain 9 289 1.3× 211 1.9× 183 2.1× 109 1.6× 68 1.0× 11 487
Davide Bosso Italy 12 132 0.6× 167 1.5× 133 1.5× 70 1.0× 21 0.3× 18 366
Ignazio Martellucci Italy 11 280 1.3× 110 1.0× 64 0.7× 73 1.0× 36 0.6× 16 356
Heejin Bang South Korea 10 142 0.6× 95 0.9× 217 2.4× 100 1.4× 68 1.0× 21 411
Bérengère Dadone France 11 120 0.5× 172 1.6× 178 2.0× 102 1.5× 64 1.0× 17 377
Valentina Tateo Italy 10 205 0.9× 150 1.4× 114 1.3× 96 1.4× 34 0.5× 36 437

Countries citing papers authored by Maria Alessandra Calegari

Since Specialization
Citations

This map shows the geographic impact of Maria Alessandra Calegari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Alessandra Calegari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Alessandra Calegari more than expected).

Fields of papers citing papers by Maria Alessandra Calegari

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Alessandra Calegari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Alessandra Calegari. The network helps show where Maria Alessandra Calegari may publish in the future.

Co-authorship network of co-authors of Maria Alessandra Calegari

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Alessandra Calegari. A scholar is included among the top collaborators of Maria Alessandra Calegari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Alessandra Calegari. Maria Alessandra Calegari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Basso, Michele, Carlo Signorelli, Maria Alessandra Calegari, et al.. (2024). Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis. Targeted Oncology. 19(3). 371–382. 1 indexed citations
4.
Moretto, Roberto, Sabina Murgioni, Marco Maria Germani, et al.. (2024). KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration. JCO Precision Oncology. 8(8). e2400329–e2400329. 1 indexed citations
5.
6.
7.
Formica, Vincenzo, Cristina Morelli, Veronica Conca, et al.. (2023). Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer—A Multicentre Propensity-Score-Matched Retrospective Analysis. Cancers. 15(11). 3064–3064. 2 indexed citations
8.
Calegari, Maria Alessandra, Michele A. Basso, Lisa Salvatore, et al.. (2023). Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer: A systematic review and bayesian network meta-analysis. Critical Reviews in Oncology/Hematology. 191. 104106–104106. 4 indexed citations
9.
Signorelli, Carlo, Marta Schirripa, Mario Giovanni Chilelli, et al.. (2023). Sequential treatment with regorafenib and trifluridine/tipiracil in later-line refractory metastatic colorectal cancer: A real-world multicenter retrospective study.. Journal of Clinical Oncology. 41(4_suppl). 45–45.
10.
Zurlo, Ina Valeria, Antonia Strippoli, Maria Alessandra Calegari, et al.. (2021). Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. Cancer Immunology Immunotherapy. 71(1). 45–55. 57 indexed citations
11.
Calegari, Maria Alessandra, Michele Basso, Carmine Carbone, et al.. (2021). Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report. Clinical Colorectal Cancer. 20(4). 364–367. 1 indexed citations
12.
Zurlo, Ina Valeria, Michele A. Basso, Antonia Strippoli, et al.. (2020). Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren’s Classification in Pan–Cancer Analysis Era?. Cancers. 12(7). 1749–1749. 18 indexed citations
13.
Calegari, Maria Alessandra, Ina Valeria Zurlo, Michele Basso, et al.. (2019). Chemotherapy rechallenge or reintroduction, regorafenib, and TAS-102 for metastatic pretreated colorectal cancer patients: a propensity score analysis of treatment beyond the second line (PROSERpINA Study). Annals of Oncology. 30. iv37–iv38. 1 indexed citations
14.
15.
Bartolomeo, Maria Di, Federica Morano, Giovanni Fucà, et al.. (2017). Selecting patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of MGMT. Annals of Oncology. 28. v41–v41. 1 indexed citations
16.
Orlandi, Armando, et al.. (2016). Paradox CA 15–3 Increase in Metastatic Breast Cancer Patients Treated with Everolimus: a Change of Paradigm in a Case Series. Biomarkers in Medicine. 10(11). 1191–1195. 3 indexed citations
17.
Orlandi, Armando, Maria Alessandra Calegari, Maurizio Martini, et al.. (2016). Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse. Clinical & Translational Oncology. 18(10). 988–995. 20 indexed citations
18.
Orlandi, Armando, Maria Alessandra Calegari, Alessandro Inno, et al.. (2015). BRAF in Metastatic Colorectal Cancer: The Future Starts Now. Pharmacogenomics. 16(18). 2069–2081. 15 indexed citations
19.
Orlandi, Armando, Mariantonietta Di Salvatore, Cinzia Bagalá, et al.. (2014). ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas. Journal of Cancer. 6(1). 70–81. 14 indexed citations
20.
Basso, Michele, Antonia Strippoli, Armando Orlandi, et al.. (2012). KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients. British Journal of Cancer. 108(1). 115–120. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kristen K. Ciombor Breakdown of academic impact, for papers by Feiyu Niu Breakdown of academic impact, for papers by Kokoro Kobayashi Breakdown of academic impact, for papers by Israel Cañadas Breakdown of academic impact, for papers by Davide Bosso Breakdown of academic impact, for papers by Ignazio Martellucci Breakdown of academic impact, for papers by Heejin Bang Breakdown of academic impact, for papers by Bérengère Dadone Breakdown of academic impact, for papers by Valentina Tateo
Rankless by CCL
2026